检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
机构地区:[1]江苏省无锡市第三人民医院,江苏无锡214000
出 处:《实用临床医药杂志》2013年第9期91-92,97,共3页Journal of Clinical Medicine in Practice
摘 要:目的评价奥尔芬联合间苯三酚治疗胆绞痛的疗效及安全性。方法将2011年3月—2012年3月于本院就诊的120例胆绞痛患者随机分为4组,每组30例。A组给予奥尔芬+间苯三酚,B组给予奥尔芬,C组给予间苯三酚,D组给予山莨菪碱。比较各组镇痛效果及不良反应发生率。结果 A、B、C、D组的镇痛总有效率分别为100.0%、76.7%、66.7%、33.3%。A组与B、C、D组镇痛效果相比较,差异有统计学意义(P<0.05);B组与C组相比较,差异无统计学意义(P>0.05);B组及C、D组相比较,差异均有统计学意义(P<0.05)。A、B、C、D组的不良反应发生率分别为6.7%、6.7%、3.3%、53.3%。A、B、C组组间比较,差异无统计学意义(P>0.05);A、B、C组与D组相比较,差异均有统计学意义(P<0.05)。结论奥尔芬联合间苯三酚治疗急性胆绞痛,疗效确切,不良反应少,值得临床推广应用。Objective To evaluate the curative effect and safety of olfen and phloroglucinol in patients with acute biliary colic.Methods A total of 120 patients with acute biliary colic of our hospital from March 2011 to March 2012 were divided into four groups randomly,group A(Olfen and Phloroglucinol,n=30),group B(olfen,n=30),group C(phloroglucinol,n=30),and group D(anisodamine,n=30).The analgesic effect and adverse reaction of four groups were observed.Results The total effectiveness rates of analgesia in groups A,B,C and D were 100%,76.7%,66.7% and 33.3%,respectively.The differences were statistically significant between group A and other three groups(P0.05).There were no statistical differences between group B and group C(P0.05),and the differences were statistically significant between group B and group C and D(P0.05).The adverse reaction rates of groups A,B,C and D were 6.7%,6.7%,3.3% and 53.3%,respectively.There were no statistical differences in groups A,B and C(P0.05),and the differences were statistically significant between group D and other three groups(P0.05).Conclusion Combined application of olfen and phloroglucinol in patients with acute biliary colic results in noticeable analgesic effect and fewer side effects.Thus it is worth clinical applications.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.211